Drugs in ATC Class P02BA

Up to Top Level ATC Classes

Up to P - Antiparasitic products, insecticides and repellents

Up to P02 - ANTHELMINTICS

Up to P02B - ANTITREMATODALS

Drugs in ATC Class: P02BA - Quinoline derivatives and related substances

Tradename	Generic Name
BILTRICIDE	praziquantel
PRAZIQUANTEL	praziquantel
VANSIL	oxamniquine

P02BA Market Analysis and Financial Projection

The ATC Class P02BA (quinoline derivatives and related substances) encompasses antiparasitic drugs critical for treating helminthic infections like schistosomiasis. This analysis examines market dynamics and patent trends shaping this therapeutic class.

Market Dynamics

Growth Drivers

• Global Disease Burden: Over 240 million people require treatment for schistosomiasis annually, driving demand for P02BA drugs like praziquantel[17][18]. Public health initiatives, such as WHO mass drug administration programs, propel market expansion.
• Pharmaceutical Innovation: Quinoline derivatives are increasingly used in oncology and metabolic disorders. For example, novel quinoline-based α-glucosidase inhibitors show promise for diabetes treatment (IC₅₀ values reaching 3.2 µM vs. 750 µM for acarbose)[14].
• Market Projections:
  • The global quinoline market is expected to grow from $369.51B (2024) to $638.74B by 2037 (4.3% CAGR)[3][7].
  • Praziquantel specifically is forecasted to rise from $0.54B (2022) to $0.87B by 2030 (6.3% CAGR)[17][18].

Regulatory Considerations

• Price Controls: Lithuania’s reference pricing system caps reimbursement costs for both patented and off-patent drugs. For off-patent drugs, prices align with the cheapest domestic version or 95% of the EU average[4][5].
• Environmental Pressures: Stricter regulations on synthetic quinoline production are accelerating R&D in bio-based alternatives[3][7].

Competitive Landscape

• Key Players: Novartis, Biogen, and GlaxoSmithKline dominate with patented formulations, while generics manufacturers like Teva and Sandoz challenge patents to expedite market entry[13][17].

• Market Segments:	Segment	Growth Driver
  Pharmaceuticals	Rising API demand for antiparasitics and specialty drugs (e.g., PI3K inhibitors)[11][16]
  Agrochemicals	Quinolines as intermediates in pesticide production[3][7]

---

Patent Landscape

Key Innovations

1. High-Purity Synthesis:

   • US11186547B2 and US10407393B2 detail methods for ≥99% pure quinoline derivatives, enhancing drug safety profiles[2][10].
   • US9802934B2 optimizes (R)-praziquantel synthesis via a 4-step stereoselective process[19].

2. Therapeutic Expansions:

   • US10689361B2 covers quinoline derivatives for angiogenesis inhibition in cancer[16].
   • US20080300239A1 describes PI3K inhibitors for autoimmune diseases[11].

Opposition Trends

Top opposed patents (2023–2025):	Patent	Assignee	Oppositions	Focus Area
EP2959894B1	Novartis	23	Multiple sclerosis
EP2653873B8	Biogen	14	MS treatment formulations
EP3448416A1	Novo Nordisk	10	Semaglutide derivatives

Generics firms filed 26% of all pharmaceutical patent oppositions in 2023–2024, targeting blockbuster drugs nearing expiration[13].

---

Strategic Implications

1. R&D Opportunities: Molecular hybridization techniques (e.g., quinoline-benzoimidazole conjugates) could yield next-generation antiparasitics and metabolic disorder therapies[14].
2. Market Entry Barriers: Patent thickets around synthesis methods (e.g., US6593343B2 for quinoline-3-carboxamides) delay generic competition[6][13].
3. Regional Dynamics: Africa and Southeast Asia present untapped potential, with 85% of schistosomiasis cases concentrated in these regions[17][18].

"Quinoline derivatives remain indispensable in addressing neglected tropical diseases, yet their evolving therapeutic applications demand continuous IP strategy refinement." – WHO Technical Report Series[8][15]

This sector’s growth hinges on balancing innovation incentives through patents with equitable access policies, particularly in low-income endemic regions.

References

1. https://www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/drug-shortages-impact.html
2. https://patents.google.com/patent/US11186547B2/en
3. https://markwideresearch.com/quinoline-market/
4. https://vvkt.lrv.lt/media/viesa/saugykla/2023/9/nvNsI8S7K9U.pdf
5. https://www.zva.gov.lv/sites/default/files/2017-12/Baltic%20Statistics%20on%20Medicines%202013%20-%202015.pdf
6. https://patents.google.com/patent/US6593343B2/en
7. https://www.researchnester.com/reports/quinoline-market/4995
8. https://www.rhsupplies.org/uploads/tx_rhscpublications/WHO_selection%20&%20use%20of%20essential%20medicines_Technical%20Report%20Series%20920_misoprostol_2003.pdf
9. https://www.fhi.no/contentassets/00c2c40952bb4c3da07216b656b72a7b/rapport-legemiddelstatistikk-2020.pdf
10. https://patents.google.com/patent/US10407393B2/en
11. https://patents.google.com/patent/US20080300239A1/en
12. https://atcddd.fhi.no/filearchive/publications/2025_guidelines__final_web.pdf
13. https://www.greyb.com/blog/oppositions-in-pharmaceutical-industry/
14. https://pmc.ncbi.nlm.nih.gov/articles/PMC9386204/
15. https://list.essentialmeds.org/files/trs/KmctuAAMtPBorqeQRged3u44S6eeGKQPvOfhGr65.pdf
16. https://patents.google.com/patent/US10689361B2/en
17. https://www.verifiedmarketreports.com/product/praziquantel-market/
18. https://www.marketresearchintellect.com/product/global-praziquantel-market/
19. https://patents.google.com/patent/US9802934B2/en
20. https://www.openpr.com/news/3930950/praziquantel-market-exploring-current-trends-and-growth